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Peripheral blood lymphocytes from both drug-in­
duced immediate and delayed cutaneous hypersensi­
tivity reactions frequently can be stimulated in vitro 
with the particular culprit drug. Immunohistochem­
ical analysis has identified CD8+ T cells as the pre­
dominant epidermal T-cell subset in drug-induced 
maculopapular and bullous eruptions and in patch­
test reactions to /l-lactam antibiotics. /l-lactam-spe­
effie peripheral and epidermal T lymphocytes from 
bullous eXanthems were preclominantly T-cell recep­
tor a//l+, CD8+, CD4-. Three CD8+ epidermal 
T-cell clones from penicillin-induced bullous exan­
thems displayed a TH1-like cytokine pattern and 
proliferated in an antigen- and major histocompati­
bility complex-speclfic manner. These epidermal T­
cell clones were cytotoxic against autologous B cells 
upon stimulation through the T-cell receptor and 
against epidermal keratinocytes in lectin-induced cy­
totoxicity assays. In contrast, peripheral T -cell lines 
from patients with penicillin-induced urticarial exan-
D rug-induced cutaneous hypersensitivity reactions represent a variety of distinct clinical entities [1]. Although immediate-type hypersensitivity reaC­tions, such as urticarial exanthems and anaphylaxis, are mediated by drug-specific 19B antibodies, the 
pathogenesis of delayed-type hypersensitivity reactions, such as 
morbilliform or bullous eruptions, has not been fully elucidated [2]. 
Sulfonamides, f3-lactam antibiotics, anti-epileptic agents (particu­
larly phenytoin), and nonsteroidal anti-inflammatory drugs are the 
major causes of drug-induced toxic epidermal necrolysis (TEN) and 
Stevens-Johnson syndrome (reviewed in [3]). There is in vivo and in 
vitro evidence that T lymphocytes are involved in the pathogenesis 
of drug-induced cutaneous reactions, in that peripheral blood 
mononuclear cells (PBMC) from patients with drug-induced im­
mediate-type reactions (urticaria) and delayed hypersensitivity re­
actions (morbilliform and bullous exanthems) frequendy can be 
stimulated in vitro with the causative drug [4,5]. In addition, several 
histologic studies have demonstrated that the inflammatory infil­
trate in drug-induced delayed cutaneous hypersensitivity reactions 
is primarily composed oflymphocytes. This brief review focuses on 
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thems were predominantly T-cell receptor a//l+, 
CD4+, COS- and displayed a Th2-like cytokine pat­
tern. CDS+ dermal T cells from a sulfamethoxazole­
induced bullous exanthem proliferated in vitro in 
response to sulfamethoxazole. This T-cell prolifera­
tion was significantly increased in the presence of 
microsomes, which suggests that microsomal en­
zymes, such as cytochrome P450 enzymes, generate 
highly reactive metabolites which are the nominal 
antigens for T-cell activation. In summary. drugs 
may be processed and presented in di1Ferent ways, 
which ill reflected by the observation that Thl-like 
CDS+ T cells are primarily activated in delayed 
cutaneous hypersensitivity reactions, whereas Th2-
like T-cell responses are present in patients with 
drug-induced urticarial exanthems. Kq ",om: cnB+ 
T cells/drug hypevsensitivity/lrmphOC}'te transjormation/,,",­
JOY histocompatibility complexlcrtochyome P450lhaptens. 
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current studies on the pathogenesis of morbilliform and bullous 
exanthems, which include the most severe drug-induced cutaneous 
hypersensitivity reactions. 
IN VIVO STUDIES 
hnmunohistochemical Findings Immunohistologic studies in 
drug-induced TEN, Stevens-Johnson syndrome, and erythema 
multiforme have shown that the dermal infiltrate is composed 
mainly of CD4+ T lymphocytes, whereas mononuclear cells 
disposed along the epidermal junction and migrating into the 
epidermis are CD8+ T lymphocytes [6-9]. Studies by Osawa et al 
[10] demons !;rated a predominance of epidermal CD8+ T cells in 
drug-induced bullous exanthems, whereas lichen planus-like and 
morbilliform exanthems were characterized by both CD4+ and 
CD8+ epidermal and dermal T cells. No definitive data are 
available regarding the frequency of drug-specific T cells in the 
epidermal and dermal infiltrate. The clinical and histologic picture 
ofTEN shows striking similarity to that of severe graft versus host 
reaction [9]. Cell-mediated cytotoxicity of lymphocytes against 
epidermal cells may explain the pathologic finding of "satellite cell 
necrosis" (necrotic keratinocytes adjacent to mononuclear cells) in 
the early phase of drug-induced TEN as in acute cutaneous graft 
vmus host reaction [9]. Most immunohistochemical studies ofTEN 
have also found variable degrees of up-regulation of intercellular 
adhesion molecule-l (IeAM-l) and human leukocyte antigen 
(HLA)-DR on keratinocytes in involved skin, which is presumably 
due to cytokine secretion by infiltrating T cells [7,8,11]. Several 
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studies have also characterized the inflammatory infiltrate of fixed 
drug eruptions [12]. As in the above-mentioned bullous exanthems, 
CDS+ T cells were the predominant epidermal subset and were 
still detectable at the epidermal junction 3 weeks after the resolu­
tion of fixed drug eruptions [13]. This persistence of potentially 
drug-specific T cells in the skin may explain why fixed drug 
eruption reappears at the same site upon rechallenge with the 
particUlar drug. A focal dysregulation of the interferon-,}, (IFN-'}')­
induced up-regulation of ICAM-l on epidermal keratinocytes has 
also been implicated as a pathogenic factor in fixed drug eruptions 
[14]. 
IN VITRO STUDIES 
Lymphocyte Transformation Test (LTT). The LIT has a 
long history as an in vitro assay for detection of drug-specific 
lymphocyte activation [4,5,15,16]. PBMC from patients with cu­
taneous hypersensitivity reactions are co-cUltured with the caus­
ative agents, and lymphocyte activation is determined after 5-7 d by 
the incorporation of radioactive thymidine [5,15]. This test has 
been reported to give positive resUlts with a variety of drugs, 
including f3-lactam antibiotics, antiepileptic agents, sulfonarnides, 
nonsteroidal anti-inflammatory drugs and others [4,5,15,16]. Per­
forming phenotypic analysis, Koponen et at [17] found that CD4+ 
T cells were the major T-cell subset activated upon co-cUlture with 
penicillins in vitro. The LTT provided some evidence that penicil­
loyl, the major metabolite of benzylpenicillin, plays a role as a 
nominal antigen in that PMBC of some penicillin-allergic patients 
were activated in vitro by both benzylpenicillin and penicilloyl [15]. 
PBMC from penicillin-allergic individuals were occasionally acti­
vated by the first-generation cephalosporin cephalothin, which is 
presumably hydrolyzed to a cephaloyl derivative that is structurally 
related to penicilloyl [15]. A major problem associated with inter­
pretation of LIT resUlts is the lack of appropriate controls, i.e., 
PBMC from healthy controls treated with the investigated drug but 
without allergic reaction. Drug-induced lymphocyte proliferation is 
frequently low, which makes it hard to distinguish between positive 
and false-negative results. This is important because PBMC from 
healthy donors can occasionally be stimulated in vitro by the tested 
drug [5,15]. In our experience, the PBMC from six of 25 healthy 
volunteers were stimUlated in vitro by benzylpenicillin; all of the 
responders had been treated with f3-lactam antibiotics in the past 
[15]. Stejskal et at [lS] also found benzylpenicillin-specific lympho­
cyte proliferation in the LIT and benzylpencillin-specific IgG 
antibodies in healthy individuals with occupational exposure to 
penicillins. Another disadvantage of the LIT is the limited knowl­
edge of the frequency of drug-specific precursor T cells in the 
peripheral blood. The lack of reproducibility of T-cell stimulation 
by the causative drug in the LTT may resUlt from low frequency of 
the drug-specific precursor cells. This is reflected by the observa­
tion of Roujeau et at [16] that the drug-induced proliferation of 
PBMC from TEN patients, seen in vitro at the onset of clinical 
symptoms, was virtually absent months later. 
Generation of Drug-Speciftc Peripheral and Lesional T­
Cell Clones From Patients With Morbilliform and Bullous 
Drug Eruptions In a recent study, exclusively CDS+ epidermal 
T-cell clones were isolated from f3-lactam-induced bullous exan­
thems and patch-test reactions [11]. Three epidermal CDS+ T-cell 
clones proliferated to the particUlar f3-lactam antibiotic in a major 
histocompatibility complex (MHC)-restricted fashion and pro­
duced TH1-pattern cytokines after activation [11]. Identical obser­
vations were made with peripheral f3-lactam-specific T-cell clones 
from patients with morbilliform exanthems, which were exclu­
sively CDS + and proliferated in response to benzylpenicillin and to 
its major metabolite penici110yl [19]. These clones also secreted 
Thl-like cytokines. The predominant generation of epidermal 
CDS+ T lymphocytes is unlikely to be a cUlture artifact in that 
CD4+ antigen-specific T-cell clones were predominantly gener-
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ated from positive epicutaneous test reactions to fragrances* and 
CD4 + T-cell lines specific for tetanus toxoid from the peripheral 
blood of immunized donors [19]. In addition, more CP4+ than 
CDS+ peripheral T-cell lines were derived from patients (n = 3) 
with penicillin-induced urticarial exanthems (unpublished observa­
tion). The CD4+ T-cell lines displayed a TH2-like cytokine pattern in 
that they produced interleukin-4 (JL-4), no IFN-,}" and low amounts 
ofIL-2. These CD4+ T cells may provide help for B cells to produce 
penicillin-specific 19B antibodies, which have a critical function in 
drug-induced immediate hypersensitivity reactions. 
Current concepts attribute two different functions to CDS+ T 
cells; an IFN-y-producing subset plays a role in cell-mediated 
cytotoxicity, and an IL-4-producing popUlation provides help for 
IgE production by B cells and suppresses the activation of CD4+ 
helper Thl-like cells [20]. Because the epidermal-derived CDS+ 
T-cell clones were cytotoxic in vitro against epidermal keratinocytes 
and B cell lines [11], we specUlate that they act as cytotoxic effector 
cells in vivo. Several studies have shown that CDS+ T-cell lines 
with cytotoxic activity can mediate delayed-type inflammatory 
reactions it, vivo [21]. It is unclear why drug-specific CDS+ T 
lymphocytes preferentially localize in the epidermis. This phenom­
enon is not unique to drug reactions; epidermal CDS+ T cells were 
also expanded from lesional skin of patients with psoriasis vUlgaris 
[22] or graft versus host disease [23]. CDS+ T lymphocytes have 
also been identified as effector cells in allergic contact dermatitis 
[24] and in humans allergic to the hapten poison ivy [25]. All 
f3-lactam-specific epidermal CDS+ T-cell clones produced signif­
icant amounts ofIFN-,}" which is known to induce up-regulation of 
ICAM-l on endothelial cells and keratinocytes [26,27]. Up-regu­
lation ofICAM-l on keratinocytes in cutaneous drug reactions may 
be due to the release of IFN-'}' by infiltrating T cells [27,2S]. 
ICAM-l, the ligand for leukocyte function-associated antigen-l on 
T cells, is a critical adhesion molecUle for the homing of T 
lymphocytes into the skin [26]. Interaction of leUkocyte function­
associated antigen-l and ICAM-l also plays a critical role in 
T-cell-mediated cytotoxicity [29]. Epidermal T cells isolated from 
various drug-induced bullous exanthems (f3-lactam antibiotics, n = 
5; carbamazepine, n = 2; sulfamethoxazole, n = 2; acetylsalicylic 
acid, n = 1) were uniformly T-cell receptor a/f3+, which is in 
keeping with the findings of Foster et at [30]. 
Role of Drug Metabolism in the Formation of the Nominal 
Antigens Most drugs are m�tabolized by cytochrome-P450-
dependent enzymes to highly reactive derivatives, which may be 
detoxified or act as a toxic agent (or immunogenic hapten) [2,4]. 
The activities of these P450-dependent isoenzymes exhibit genetic 
polymorphism, and the genes of more than 300 isoenzymes have 
already been cloned; this may explain the heterogeneity of the 
individual response to the particUlar drug. 
. 
Phenytoin is metabolized by cytochrome-P450-dependent en­
zymes into a highly reactive arene-oxide metabolite, which is 
detoxified primarily by epoxide hydrolases [31,32]. This compound 
is highly toxic to cells but may also bind to proteins. The increased 
toxicity of phenytoin to lymphocytes of phenytoin-allergic patients 
indicates that a polymorphism in the activity of the epoxide hydrolase 
may be the cause for this syndrome [31]. Shear and Spielberg [31] 
prop.osed the use of the lymphocyte toxicity assay for in vitro diaguosis 
of the phenytoin hypersensitivity syndrome because PBMC from. 
patients with this syndrome are highly susceptible to the toxic effects of 
cytochrome-P450-dependent metabolites of most (not chemically 
related) anti-epileptic drugs, including phenytoin, carbamazepine, and 
phenobarbital (though not valproinic acid). 
Sulfamethoxazole (SMX) is metabolized by acetylation to N4-
cetyl-SMX and by cytochrome P450 to 5-hydroxy-SMX or to a 
reactive hydroxylamine [33,34]. The hydoxylamine derivative may 
be detoxified by glutathione synthetase or may bind to macromol-
• Niederau D, Hertl M, Boecker C, Geisel], Merk H: CD4+ antigen­
specific cytotoxic T lymphocytes are present in contact hypersensitivity 
reactions to fragrances (abstr).] Invest Dermatol102:480A, 1994. 
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ecules to form an immunogen [33]. Cytochrome-P450-dependent 
SMX metabolites may be important in the pathogenesis of SMX­
induced hypersensitivity reactions because an SMX-specific CD8+ 
dermal T-cell clone from an SMX-induced bullous exanthem 
showed a significantly increased proliferation to SMX in the 
presence of microsomes rich in cytochrome P450 [34]. This 
observation suggests that cytochrome,.P450-dependent SMX me­
tabolites were relevant T-cell antigens. This finding is of particular 
interes� because recent studies have indicate.d that some patients 
with sulfunamide-induced bullous C\ltaneous eruptions exhibit 
reduced N-acetylating capacity.:j: In addition, patients with in­
creased cytochrome-P450-dependent metabolism of sulfonamides 
to hydroxylamine derivatives have an increased risk to develop 
drug-induced hypersensitivity reactions [3 5]. Analogous to the 
findings in the phenytoin hypersensitivity syndrome, the toxicity of 
the hydroxylamine metabolite of SMX was greatest for PBMC 
from SMX-allergic patients [2,34]. Kalish et al [36 ] have also 
demonstrated that T lymphocytes reactive to SMX are present at 
low frequencies in the peripheral blood of patients with drug 
eruptions secondary to treatment with s,*,onamides. Maurl-Hell­
weg et al observed an increased express ion of CD25 (lL-2R) and 
lILA-DR (MHC IT) on peripheral CD4+ and CD8+ T cells from 
allergic donors stimulated in vitro with SMX.§ Supernatants from 
these cultures contained high amounts ofIL-5, which was presum­
ably produced by SMX-activated T cells. In vitro cultures with SMx 
in�ced the preferential expansion of CD25+ T-cell receptor 
V/U 7 + T cells, suggesting that: �g-activated T cells displayed a 
limited T-cell receptor usage. 
Niederau et al [37] have also provided evidence for the role of 
cytochrome-P450-dependent enzymes in the generation of the 
nominal antigens recognized by lymphocytes from pyrazolone­
sensitized individuals. PBMC from eight patients with hypersensi­
tivity reactions to the pyrazolone derivatives metamizole, propy­
phenazone , and phenazone were strongly stimulated by these 4rugs 
in the presence of cytochrome-P450-enriched microsomes, 
whereas co-culture with the parent drugs alone caused absent or 
significantly less lymphocyte proliferation. 
Penicillins hydrolyze spontaneously to form a penicilloyl group 
(which can covalendy bind to either amino or sulfhydryl groups of 
proteins) and to the so -called minor determinants [38-40]. The 
relevance of the binding of penicilloyl to albumin has been 
confirmed in vivo in that patients receiving benzylpenicillin showed 
a dose-dependent saturation of serum albumin with penicilloyl [40]. 
As mentioned earlier, penicilloyl can stimulate penicillin-specific T 
cells [15,34]. The penicillin-specific IgE antibody response is 
heterogeneous in that antibodies against the common J:J-lactam ring 
structure and various side-chain determinants are present in the sera 
of penicillin-allergic patients [39]. In many instances, only antibod­
ies against the side-chain determinants of 13-lactam antibiotics are 
found [ 9,18]. Side-chain-specific lymphocyte proliferation has been 
demonstrated in individuals with occupational exposure to the 
ampicillin derivative a-aminobenzylpenidllin ester (bacampicillin). 
In these patients, FUMC proliferated in response to the N-acyl­
amido side chain and the ester group of the bacampicillin molecule, 
but not to benzylpenicilliit, penicillin V, or 6-aminopenicillanic acid 
[18]. In addition, PBMC from ampicillin-allergic patients were 
activated in vitro by ampicillin but not by benzylpenicillin [41,42]. 
Penicilloyl-specific IgG antibodies can be found in the sera of 
healthy individuals treated with petrlci11ins [40]. However, the 
presence of benzylpenicillin-specific 19B antibodies is generally 
linked to the occurrence of penicillin-induced allergic reactions 
[40]. 
:j: Dietrich A, Kawakubo Y, Rzany B, SchOpf E: Patients with severe 
cutaneous drug reactions (EM,S]S,TEN) ha"\'e a reduced N-acetylating 
capacity (abstt).} Invest Dermatoll00:519A, 1993. 
§ Mauri-Hellweg D, Bettens F, Mauri D, Brander C, Hunziker T, Pichler 
W: Activation of drug-specific CD4+ and CD8+ T cel\s in individuals 
allergic to sulfunarnides, phenytoin and carbamazepine (submitted). 
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Molecular Mechanisms of Drug-Induced T-cell Activation 
Haptens , such as drugs and small-molecular-weight contact sensi­
tizers, interact with proteins by a variety of cheniical reactions and 
have a broad range of physical properties [4,43]. This diversity in 
hapten chemistry is probably reflected in diversity of antigen 
processing and presentation. Functional data suggest that drugs 
preferentially activate (:D8+ T cells but also activate CD4+ T cells 
[11,19,34]. The predominant activation QfCD8+ T cells suggests 
that the processing of drug-conjugated proteins proceeds by the 
endogenous pathway. Because most drugs are exogenoqs sub­
stances , they may be internalized, conjugated to intracellular 
proteins, and presented by MHC I molecules to CD8+ T cells. The 
penicilloyl moiety, the major penicillin metabolite [38,39]. seems to 
playa role in penicillin-specific T-cell �tivation , as benzylpenicil­
lin-specific CD8+ T-cell clones were also significantly stimulated 
by penicilloyl [ 34] . Pichler [5] reported that PBMC from penicillin­
allergic patients can be optimally stimulated in vitro with unmodi­
fied benzylpenicillin. In some instances, less vigorous in vitro 
lymphocyte stimulation could also be achieved with benzylpenicil­
lin coupled to albumin [ 5]. Bell and Pichler [44] found that 
glutaraldehyde-fixed antigen-presenting cells acted as sufficient 
antigen-presenting cells for penicillin-induced T-cell proliferation, 
suggest:ip.g that penicillin can bind directly to MHC molecules or 
MHC-associated endogenous peptides . Direct interaction with 
MHC II molecules has been demonstrated for the hapten gold [45]. 
In our experience, paraformaldehyde fixation significantly dimin­
ished the ability of Epstein-Barr virut-transformed B-cell lines to 
present benzylpenicillin to benzylpenicillin-specific CD8+ T-cell 
clones, suggesting that processing was required [11]. Regarding the 
nature of the complete antigen, Claas et al [46] demonstrated that 
benzylpenicillin-treated lymphocytes are no longer susceptible to 
the cytotoxicity of HLA typing sera against certain MHC I haplo­
types. This observation suggests that penicillins bind to MHC I 
antigens. Sparse evidence for the preferential association of drugs 
with certain MHC haplotypes is given from linkage studies based 
on the MHC haplotypes of patients with drug-induced cutaneous 
hypersensitivity reactions [47]: sulfonamide-induced TEN is asso­
ciated with lILA-A29, HLA-BI2, and HLA-DR7; and so is sulfon­
amide-induced Stevens-Johnson syndrome (HLA-A29, m.A-B44, 
HLA-DR7). Herpes simplex-associated erythema multiforme is 
linked to HLA-BI2 and m.A..,DQ3. 
SUMMARY AND CONCLUSIONS 
Drug-specific CD8+ T lymphocytes are present in the peripheral 
blood and involved skin of patients with drug-induced delayed 
cutaneous hypersensitivity reactions, such as morbilliform and 
bullous exanthems. The observed predominance of cytotoxic epi­
dermlll CD8+ T lymphocytes in drug-induced bullous exanthems 
suggests that this particular T-cell subset plays a role in the 
pathogenesis of drug-induced blister formation. In contrast , there is 
evidence that CD4+ T cells with a TH2-like cytokine pattern are 
preferentially activated in IgE-mediated cutaneous drug reactions. 
The metabolism of the many drugs, for example by cytochrome­
P450-dependent enzymes, is critical in the formation of the 
nominal T-cell antigens, as demonstrated in the case of SMX­
dependent T-cell activation. Because of the c�emical properties of 
haptenic drugs, there seems to be a diversity of processing and 
presentation pathways of drugs, which is reflected in the activation 
of both CD8+ THl-like cells in bullous exanthems and CD4+ 
TH2-like T lymphocytes in 19B-mediated immediate hypersensi­
tivity reactions. 
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